PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.31%
Revenue growth above 1.5x AVGO's 0.59%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
3.64%
Gross profit growth above 1.5x AVGO's 0.51%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
12.92%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
10.33%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
34.92%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
33.33%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
33.33%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-29.56%
Share reduction while AVGO is at 0.26%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-27.87%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
41.96%
Dividend growth above 1.5x AVGO's 0.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-48.82%
Negative OCF growth while AVGO is at 7.23%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-112.03%
Negative FCF growth while AVGO is at 6.62%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
3.06%
10Y revenue/share CAGR under 50% of AVGO's 409.54%. Michael Burry would suspect a lasting competitive disadvantage.
-24.01%
Negative 5Y CAGR while AVGO stands at 122.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-27.73%
Negative 3Y CAGR while AVGO stands at 60.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
-52.04%
Negative 5Y OCF/share CAGR while AVGO is at 73.80%. Joel Greenblatt would question the firm’s operational model or cost structure.
385.77%
3Y OCF/share CAGR above 1.5x AVGO's 34.25%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
143.28%
Below 50% of AVGO's 691.11%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
73.69%
Below 50% of AVGO's 651.30%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
48.33%
3Y net income/share CAGR 50-75% of AVGO's 66.58%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
145.52%
5Y equity/share CAGR is in line with AVGO's 147.32%. Walter Schloss would see parallel mid-term profitability and retention policies.
49.68%
Below 50% of AVGO's 188.08%. Michael Burry suspects a serious short-term disadvantage in building book value.
83.48%
Below 50% of AVGO's 1441.93%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
77.18%
Similar 5Y dividend/share CAGR to AVGO's 71.80%. Walter Schloss sees parallel philosophies in mid-term capital returns.
-2.22%
Negative near-term dividend growth while AVGO invests at 38.29%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
7.14%
AR growth is negative/stable vs. AVGO's 14.59%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
3.72%
Inventory growth well above AVGO's 5.71%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
45.27%
Positive BV/share change while AVGO is negative. John Neff sees a clear edge over a competitor losing equity.
-3.48%
We’re deleveraging while AVGO stands at 1.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.68%
R&D growth drastically higher vs. AVGO's 19.53%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-1.52%
We cut SG&A while AVGO invests at 14.12%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.